Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Koontz, BF; Hoffman, KE; Healy, P; George, DJ; Harrison, MR; Zhang, T; Lee, WR; Berry, WR; Pugh, TJ; Corn, PG; Bratt, L; Shobe, K; Thornburg, B; Allen, DM; Brummer, K; Tojong, B; Hobbs, B; Halabi, S; Armstrong, AJ

Published Date

  • February 20, 2018

Published In

Volume / Issue

  • 36 / 6_suppl

Start / End Page

  • 11 - 11

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2018.36.6_suppl.11